Walvax Biotechnology Walvax Biotechnology (also known as Yunnan Watson Biotechnology, 云南沃森生物技术股份有限公司) is a company that is engaged in the research and development, production, and sales of human vaccines and biotechnology drugs. | Biohaven Pharmaceutical Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. | Shandong Saito Biotechnology Shandong Saito Biotechnology (山东斋藤生物科技) is a company that is engaged in the research and development and production of steroid drug intermediates. | ||
Founding Date | Founding Date 1916 | Founding Date 2001 | Founding Date 2014 | Founding Date 2010 |
Type | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | ||||
Locations | Locations Parkville, AU HQ King Of Prussia, US | Locations Kunming, CN HQ | Locations New Haven, US HQ | Locations Heze, CN HQ |
Employees | Employees 32,6982% increase | Employees 2,388 | Employees 4692% decrease | Employees 1,200 |
Valuation ($) | Valuation ($) 95.1 b | Valuation ($) 3.4 b | Valuation ($) N/A | Valuation ($) 620.9 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $14.7b (FY, 2024) | Revenue (est.) ¥4.1b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) ¥1.2b (FY, 2023) |
Cost of goods | Cost of goods $6.2b (FY, 2024) | Cost of goods ¥597.6m (FY, 2023) | Cost of goods N/A | Cost of goods ¥994.2m (FY, 2023) |
Gross profit | Gross profit $8.6b (FY, 2024) | Gross profit ¥3.5b (FY, 2023) | Gross profit N/A | Gross profit ¥271.8m (FY, 2023) |
Net income | Net income $2.7b (FY, 2024) | Net income ¥511.3m (FY, 2023) | Net income N/A | Net income ¥48.5m (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 72.8m | Total funding raised $ 80m | Total funding raised N/A |